Nasdaq apls.
During the recent session, Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s traded shares were 1.43 million, with the beta value of the company hitting 0.96. At the last check today, the stock’s price was $57.36, reflecting an intraday gain of 6.48% or $3.49. The 52-week high for the APLS share is $ ...
Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 8563830 shares of its common stock at ...On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company and is a trending biotech stock to watch in the stock market as of late. This came after the company’s EMPAVELI ...
14 analysts have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they anticipate the company's share price to reach $66.50 in the next twelve months. This suggests a possible upside of 8.0% from the stock's current price.WALTHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...
On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 20 new employees with a ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Bill Oxford/iStock via Getty Images. Apellis Pharmaceuticals (NASDAQ:APLS) and Beam Therapeutics (NASDAQ:BEAM) will collaborate to develop therapies for complement-driven diseases.; The body's ...
Dec 1, 2023 · Apellis Pharmaceuticals last released its quarterly earnings data on November 1st, 2023. The reported ($1.17) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by $0.29. The firm earned $110.40 million during the quarter, compared to the consensus estimate of $99.05 million. Its revenue was up 400.5% on a year-over-year basis.
On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that specializes in discovering, developing, and selling therapeutic compounds that work by inhibiting ...Number of Hedge Fund Shareholders: 36. The number of hedge funds long Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has ticked up steadily over each of the past four quarters, more than doubling ...JPMorgan upgraded Apellis Pharmaceuticals (NASDAQ: APLS) to Overweight from Neutral, with a new price target of $81, up from $60 per share in a note Friday. Analysts told investors the Syfovre ...Apellis Pharmaceuticals, Inc. (APLS). NASDAQ: APLS · IEX Real-Time Price · USD.The latest price target for . Apellis Pharmaceuticals (NASDAQ: APLS) was reported by Goldman Sachs on November 9, 2023.The analyst firm set a price target for $74.00 expecting APLS to rise to ...
That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ...WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...Apr 7, 2023 · The firm decreased its portfolio allocation in APLS by 48.09% over the last quarter. GSAOX - Goldman Sachs Small Cap Growth Insights Fund holds 13K shares representing 0.01% ownership of the company. Apellis Pharmaceuticals ( NASDAQ: APLS) can't seem to shake off safety concerns with its vision loss drug Syfovre (pegcetacoplan) and is down another ~6% on Tuesday. Adding to the company's woes ...WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET. The conference will be …Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Apellis Pharmaceuticals Inc (Symbol: APLS), where a total of 7,621 contracts have ...CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...
Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. …Apellis Pharmaceuticals, Inc. APLS reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65. The loss was also narrower than our ...
Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Follow. WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of ...Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com. NASDAQ: APLS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Apellis Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. ... NASDAQ: Apellis Pharmaceuticals Inc Performance. USD USD; Diluted EPS (TTM)-5.23 …CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 30 months of continuous treatment with ...
WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on ...
9 de set. de 2023 ... Fintel reports that on September 8, 2023, B of A Securities maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral ...
LOS ANGELES, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) investors that a lawsuit filed on behalf of investors that purchased ...Feb 22, 2023 · With the business potentially at an important milestone, we thought we'd take a closer look at Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) future prospects. Apellis Pharmaceuticals, Inc., a ... Hedge funds poured into Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in even greater numbers during Q2, as the number of funds long APLS rose by 27% to reach a new all-time high and propel it to ...Nov 30, 2023 · For instance, the price of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock is up an impressive 177% over the last five years. It's also good to see the share price up 19% over the last quarter. ... Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? 3 days ago · Yahoo Finance. Apellis Pharmaceuticals' (NASDAQ:APLS) growing losses don't ...Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week May 13. Consensus revenue estimates increase by 57%, …View live Apellis Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, APLS financials and market news.Apellis Pharmaceuticals APLS WideScreen charts, DMA,SMA,EMA technical analysis, forecast prediction, by indicators ADX,MACD,RSI,CCI NASDAQ stock exchange.WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that five abstracts ...Analyst Price Forecast Suggests 156.95% Upside. As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high of ...31 de jul. de 2023 ... On today's stock market, APLS stock plummeted 19.6% to close at 25.75. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade ...Nov 17, 2023 · Apellis Pharmaceuticals Inc (NASDAQ:APLS) showed a performance of 4.00% in past 30-days. Number of shares sold short was 16.23 million shares which calculate 7.13 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $71.19 to the stock, which implies a rise of 32.73% to its current value.
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...Dec 1, 2023 · Apellis Pharmaceuticals last released its quarterly earnings data on November 1st, 2023. The reported ($1.17) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by $0.29. The firm earned $110.40 million during the quarter, compared to the consensus estimate of $99.05 million. Its revenue was up 400.5% on a year-over-year basis. Dec 1, 2023 · The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors? Instagram:https://instagram. cobalt companies stockbest utility dividend stocksgolden oceansaga falabella lima peru Nov 24, 2023 · Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s stock price traded down 3.7% on Wednesday after an insider sold shares in the company. The stock traded as low as $47.20 and last traded at $47.55. 370,506 shares changed hands during trading, a decline of 86% from the average session volume of 2,690,365 shares. The stock […] best global stock etfjim cramer apple price target The APLS stock price is -107.15% off its 52-week high price of $94.75 and 56.65% above the 52-week low of $19.83. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.29 million shares traded. The 3-month trading volume is 3.02 million shares. Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information cyber security stock Apellis Pharmaceuticals Stock Down 1.9 %. Shares of NASDAQ:APLS opened at $60.40 on Monday. The company’s fifty day moving average price is $46.23 and its 200 day moving average price is $55.22.About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Nasdaq MarketSIte. Do Not Sell My Personal Information (CA ...Apellis Pharmaceuticals (NASDAQ: APLS) layoffs are a hot topic on Tuesday as the commercial-stage biopharmaceutical company prepares for job cuts.. Apellis Pharmaceuticals has announced that it ...